Federal regulators are caught between old-guard conservatives who demand continued mRNA funding, Rep. Massie's demand to ...

Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today reported financial results for the second ...

Kennedy’s $500M cut to mRNA funding puts startups at risk and imperils one of life sciences’ few leasing bright spots.

Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

About Vepdegestrant Vepdegestrant is an investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) estrogen receptor degrader. Vepdegestrant is being developed as a potential ...

With a 5.98% market share, India is the fourth-largest pharmaceutical supplier to the U.S., behind Ireland, Switzerland, and ...

Californians are trading in their sun-filled coastal lives for this undiscovered paradise - as locals reveal the incredible ...

Let's see why these funds could be worth holding onto for the long term. The post 5 high-quality ASX ETFs to buy and hold for ...